

Kevin G Pinney

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7785385/publications.pdf>

Version: 2024-02-01

77
papers

1,879
citations

236925

25
h-index

265206

42
g-index

81
all docs

81
docs citations

81
times ranked

1849
citing authors

#	ARTICLE	IF	CITATIONS
1	Stereoselective synthesis of 2,5-dihydrofurans by sequential SN2' cleavage of alkynylloxiranes and silver(I)-catalyzed cyclization of the allenylcarbinol products. <i>Journal of Organic Chemistry</i> , 1993, 58, 7180-7184.	3.2	187
2	A new anti-tubulin agent containing the benzo[b]thiophene ring system. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1999, 9, 1081-1086.	2.2	115
3	A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. <i>Integrative Biology (United Kingdom)</i> , 2011, 3, 375.	1.3	87
4	Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis. <i>International Journal of Cancer</i> , 2004, 111, 604-610.	5.1	80
5	Synthesis and biological evaluation of aryl azide derivatives of combretastatin a-4 as molecular probes for tubulin. <i>Bioorganic and Medicinal Chemistry</i> , 2000, 8, 2417-2425.	3.0	77
6	Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 3231-3244.	3.0	73
7	Design, synthesis and biological evaluation of dihydronaphthalene and benzosuberene analogs of the combretastatins as inhibitors of tubulin polymerization in cancer chemotherapy. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 8161-8171.	3.0	71
8	Design, synthesis, and biochemical evaluation of novel cruzain inhibitors with potential application in the treatment of Chagas's™ disease. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 4405-4409.	2.2	68
9	Synthesis of a tetrafluoro-substituted aryl azide and its protio analog as photoaffinity labeling reagents for the estrogen receptor. <i>Journal of Organic Chemistry</i> , 1991, 56, 3125-3133.	3.2	63
10	Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3-hydroxy-4-methoxyphenyl)-3-(3,4,5-trimethoxybenzoyl)-6-methoxyindole (OXI8006). <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6831-6843.	3.0	58
11	Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. <i>Anticancer Research</i> , 2003, 23, 1433-40.	1.1	52
12	Synthesis of a 2-Aryl-3-aryl Indole Salt (OXI8007) Resembling Combretastatin A-4 with Application as a Vascular Disrupting Agent. <i>Journal of Natural Products</i> , 2013, 76, 1668-1678.	3.0	50
13	Preparation of New Anti-Tubulin Ligands through a Dual-Mode, Addition-Elimination Reaction to a Bromo-Substituted β,β -Unsaturated Sulfoxide. <i>Journal of Organic Chemistry</i> , 2000, 65, 8811-8815.	3.2	44
14	Efficient and selective photoaffinity labeling of the estrogen receptor using two nonsteroidal ligands that embody aryl azide or tetrafluoroaryl azide photoreactive functions. <i>Biochemistry</i> , 1991, 30, 2421-2431.	2.5	41
15	Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 1415-1419.	2.2	39
16	Combretastatin Dinitrogen-Substituted Stilbene Analogues as Tubulin-Binding and Vascular-Disrupting Agents. <i>Journal of Natural Products</i> , 2008, 71, 313-320.	3.0	38
17	Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents. <i>Bioorganic and Medicinal Chemistry</i> , 2016, 24, 938-956.	3.0	37
18	Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 6610-6615.	2.2	36

#	ARTICLE	IF	CITATIONS
19	Synthesis and biological evaluation of benzocyclooctene-based and indene-based anticancer agents that function as inhibitors of tubulin polymerization. <i>MedChemComm</i> , 2016, 7, 2418-2427.	3.4	35
20	Molecular structures, conformational analysis, and preferential modes of binding of 3-aryl-2-arylbenzo[b]thiophene estrogen receptor ligands: LY117018 and aryl azide photoaffinity labeling analogs. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 3910-3922.	6.4	32
21	Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L. <i>European Journal of Medicinal Chemistry</i> , 2012, 58, 568-572.	5.5	29
22	Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 8019-8032.	3.0	29
23	Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1505-1508.	2.2	28
24	Development of Synthetic Methodology Suitable for the Radiosynthesis of Combretastatin A-1 (CA1) and Its Corresponding Prodrug CA1P. <i>Journal of Natural Products</i> , 2009, 72, 414-421.	3.0	26
25	The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts. <i>Cancer Letters</i> , 2015, 369, 229-241.	7.2	26
26	Synthesis and Biochemical Evaluation of Thiochromanone Thiosemicarbazone Analogues as Inhibitors of Cathepsin L. <i>ACS Medicinal Chemistry Letters</i> , 2012, 3, 450-453.	2.8	25
27	Torsionally and hydrophobically modified 2,3-diarylindenes as estrogen-receptor ligands. <i>Journal of Medicinal Chemistry</i> , 1990, 33, 2726-2734.	6.4	23
28	An amino-benzosuberene analogue that inhibits tubulin assembly and demonstrates remarkable cytotoxicity. <i>MedChemComm</i> , 2012, 3, 720.	3.4	23
29	Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 6974-6992.	3.0	23
30	Synthesis of methoxy and hydroxy containing tetralones: versatile intermediates for the preparation of biologically relevant molecules. <i>Tetrahedron Letters</i> , 2003, 44, 4145-4148.	1.4	21
31	Synthesis and characterization of 2,6-bis-hydrazinopyridine, and its conversion to 2,6-bis-pyrazolopyridines. <i>Tetrahedron</i> , 2006, 62, 3663-3666.	1.9	21
32	Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5146-5149.	2.2	20
33	Application of the McMurry coupling reaction in the synthesis of tri- and tetra-arylethylene analogues as potential cancer chemotherapeutic agents. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6993-7001.	3.0	20
34	Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 2801-2807.	2.2	19
35	Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 7497-7520.	3.0	19
36	Structure Guided Design, Synthesis, and Biological Evaluation of Novel Benzosuberene Analogues as Inhibitors of Tubulin Polymerization. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 5594-5615.	6.4	19

#	ARTICLE	IF	CITATIONS
37	[3H]DU41165: A high affinity ligand and novel photoaffinity labeling reagent for the progesterone receptor. <i>The Journal of Steroid Biochemistry</i> , 1990, 35, 179-189.	1.1	17
38	2-(3-tert-Butyldimethylsiloxy-4-methoxyphenyl)-6-methoxy-3-(3,4,5-trimethoxybenzoyl)indole. <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 2002, 58, o330-o332.	0.4	16
39	Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents. <i>MedChemComm</i> , 2018, 9, 1649-1662.	3.4	15
40	Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia. <i>Journal of Natural Products</i> , 2020, 83, 937-954.	3.0	15
41	Target tissue uptake selectivity of three fluorine-substituted progestins: Potential imaging agents for receptor-positive breast tumors. <i>International Journal of Radiation Applications and Instrumentation Part B, Nuclear Medicine and Biology</i> , 1990, 17, 309-319.	0.3	13
42	Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 636-641.	2.2	13
43	Improved Methodology for the Synthesis of a Cathepsin B Cleavable Dipeptide Linker, Widely Used in Antibody-Drug Conjugate Research. <i>Tetrahedron Letters</i> , 2018, 59, 3594-3599.	1.4	13
44	Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 5, 143-53.	1.0	12
45	Regioselective Synthesis of Water-Soluble Monophosphate Derivatives of Combretastatin A-1. <i>Journal of Natural Products</i> , 2011, 74, 1568-1574.	3.0	11
46	Non-Invasive Evaluation of Acute Effects of Tubulin Binding Agents: A Review of Imaging Vascular Disruption in Tumors. <i>Molecules</i> , 2021, 26, 2551.	3.8	11
47	Synthesis and biological evaluation of 2-(4-fluorophenoxy)-2-phenyl-ethyl piperazines as serotonin-selective reuptake inhibitors with a potentially improved adverse reaction profile. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 1483-1491.	3.0	10
48	Characterization and structural analyses of trimethoxy and triethoxybenzo[b]thiophene. <i>Journal of Chemical Crystallography</i> , 1998, 28, 289-295.	1.1	9
49	Regio- and Stereospecific Synthesis of Mono- ¹⁴ C-Glucuronic Acid Derivatives of Combretastatin A-1. <i>Journal of Natural Products</i> , 2010, 73, 1093-1101.	3.0	9
50	Synthesis and biological evaluation of structurally diverse β -conformationally restricted chalcones and related analogues. <i>MedChemComm</i> , 2019, 10, 1445-1456.	3.4	9
51	Nonsteroidal estrogens bearing acyl azide functions: potential electrophilic and photoaffinity labeling agents for the estrogen receptor. <i>Steroids</i> , 1992, 57, 222-232.	1.8	7
52	Molecular Recognition of the Colchicine Binding Site as a Design Paradigm for the Discovery and Development of Vascular Disrupting Agents. , 2006, , 95-121.		6
53	Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1304-1310.	2.2	6
54	Imaging-Guided Evaluation of the Novel Small-Molecule Benzosuberene Tubulin-Binding Agent KGP265 as a Potential Therapeutic Agent for Cancer Treatment. <i>Cancers</i> , 2021, 13, 4769.	3.7	6

#	ARTICLE	IF	CITATIONS
55	Efficient synthetic methodology for the construction of dihydronaphthalene and benzosuberene molecular frameworks. <i>Tetrahedron Letters</i> , 2019, 60, 397-401.	1.4	5
56	Mechanistic considerations in the synthesis of 2-aryl-indole analogues under Bischler-Mohr conditions. <i>Tetrahedron Letters</i> , 2015, 56, 3624-3629.	1.4	4
57	X-ray structures of two methoxybenzo[b]thiophenes. <i>Journal of Chemical Crystallography</i> , 1996, 26, 801-806.	1.1	3
58	Synthesis of 4-methoxy-3,5-dinitrobenzaldehyde: a correction to supposed tele nucleophilic aromatic substitution. <i>Tetrahedron Letters</i> , 2003, 44, 3759-3761.	1.4	3
59	The Discovery and Development of the Combretastatins. , 2011, , 27-64.		3
60	Carbon-14 radiosynthesis of combretastatin A-1 (CA1) and its corresponding phosphate prodrug (CA1P). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2009, 52, 567-570.	1.0	2
61	Synthesis and crystal structures of two novel 3,4,5- trimethoxyphenyl derivatives from (Z)-1-[(2,3-dinitro-4-methoxy)-phenyl]-2-[(3,4,5-trimethoxy)-phenyl]ethene. <i>Journal of Chemical Crystallography</i> , 2006, 36, 309-314.		1
62	Abstract 1416: Development and initial evaluation of the antitumor activity of a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L. <i>Cancer Research</i> , 2011, 71, 1416-1416.	0.9	1
63	Abstract 4194: Assessment of novel benzosuberene-based vascular disrupting agents (VDA) on diverse tumor lines. , 2016, , .		1
64	The Discovery and Development of the Combretastatins. , 2005, , .		1
65	Synthesis of Methoxy and Hydroxy Containing Tetralones: Versatile Intermediates for the Preparation of Biologically Relevant Molecules.. <i>ChemInform</i> , 2003, 34, no.	0.0	0
66	Release of Anticancer Agents in the Tumor Microenvironment Using Cathepsin B and Cathepsin L Cleavable Drug-Linker Constructs. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
67	Inhibitors of cruzipain and cathepsin L. <i>FASEB Journal</i> , 2006, 20, A51.	0.5	0
68	Kinetic Studies of Potent Thiosemicarbazone Inhibitors of Cruzain. <i>FASEB Journal</i> , 2007, 21, A641.	0.5	0
69	Kinetics of Thiosemicarbazone-Based Inhibitors of Cathepsin L. <i>FASEB Journal</i> , 2007, 21, A642.	0.5	0
70	Analysis of novel low nanomolar thiosemicarbazone inhibitors of cruzain. <i>FASEB Journal</i> , 2010, 24, 681.5.	0.5	0
71	Kinetic Analysis and Antitumor Activity of Thiosemicarbazone Benzophenone Inhibitors of cathepsin L. <i>FASEB Journal</i> , 2012, 26, 962.7.	0.5	0
72	The effect of benzosuberene analogues on endothelial cell morphology and tube formation. <i>FASEB Journal</i> , 2012, 26, 999.8.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Study of a Potent Small-Molecule Benzosuberene Anti-Cancer Agent. FASEB Journal, 2012, 26, 613.5.	0.5	0
74	Abstract 5071: KGP94, a small-molecule cathepsin L inhibitor with antitumor activity.. , 2013, , .		0
75	Abstract 1816: Assessment of anti-tumor activity of the cathepsin L inhibitor, KGP94. , 2014, , .		0
76	Vascular Disrupting Activity of OXi8006 in Endothelial Cells and Its Phosphate Prodrug OXi8007 in Breast Tumor Xenografts in Vivo. FASEB Journal, 2015, 29, 897.5.	0.5	0
77	Mechanism of action of the vascular disrupting agent OXi8006 on activated endothelial cell signaling. FASEB Journal, 2018, 32, 804.58.	0.5	0